Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615
This examiner grants 55% of resolved cases
Olga V. Tcherkasskaya works in Tech Center 1600 and Art Unit 1615. The examiner has 845 resolved cases and an allowance rate of 55.4 percent. A standout figure is the interview lift of 46.2 percent, which is a significant increase in the probability of allowance. This suggests that interviews are a vital component for success with this examiner. Practitioners should prioritize scheduling an interview to navigate the 979-day median pendency.
The 55.4 percent allowance rate provides a baseline for applications in Art Unit 1615. While this rate is moderate, the 46.2 percent interview lift offers a clear path forward for the 845 cases handled. The median days to allowance of 979 reflects the typical prosecution cycle. Direct communication can be used to address rejections and move toward a grant. The data indicates that verbal engagement is highly effective for applications assigned to this docket in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16707580 | ORAL PRODUCT AND METHOD OF MANUFACTURE | Non-Final OA | NICOVENTURES TRADING LIMITED |
| 19371866 | FORMULATIONS COMPRISING INOSITOL, SILICATES, AND OPTIONALLY AMINO ACIDS WITH IMPROVED SOLUBILITY AND METHODS OF MAKING THE SAME | Final Rejection | Nutrition21, LLC |
| 18683624 | PATCH AND PRODUCTION METHOD THEREOF | Final Rejection | KANEKA CORPORATION |
| 18860504 | COMPOSITION FOR DYEING HAIR | Non-Final OA | LG H&H CO., LTD. |
| 17284947 | Softgels with solid or gel-like polymeric fill matrix | Final Rejection | Bayer HealthCare LLC |
| 18870200 | HERBICIDAL DERIVATIVES | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18849295 | COMPOSITIONS AND METHODS FOR CONTROLLING INSECTS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18549652 | LIQUID VISCOELASTIC SWALLOWING AID TO PROMOTE SAFE SWALLOWING OF SOLID ORAL DOSAGE FORMS (SODF) | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18456763 | CHEWABLE DISSOLVABLE NICOTINE TABLET | Final Rejection | Altria Client Services LLC |
| 19076661 | STABLE PHARMACEUTICAL COMPOSITION OF AN AMINE DRUG | Non-Final OA | SUN PHARMACEUTICAL INDUSTRIES LIMITED |
| 18199614 | DRUG COMPOSITIONS AND METHODS OF PREPARING THE SAME | Non-Final OA | Applied Materials, Inc. |
| 18853162 | BIODEGRADABLE LIPIDOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF FOR LIVER TARGETED DELIVERY | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18287244 | CAPSULE FOR SPECIFIC DRUG DELIVERY AND PREPARATION METHOD THEREFOR | Non-Final OA | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. |
| 18262938 | ORAL SOLID DOSE FORMULATIONS | Final Rejection | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED |
| 18861479 | METHOD AND COMPOSITION FOR TREATING LUNG DISEASES | Non-Final OA | MannKind Corporation |
| 18800988 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | Non-Final OA | Celgene Corporation |
| 18746814 | PHARMACEUTICAL DOSAGE FORMS | Final Rejection | Purdue Pharma L.P. |
| 18411193 | Pharmaceutical Composition and Method for Improving Biomechanical Integrity of the Pelvic Floor | Final Rejection | Fempharma, LLC |
| 17470994 | METHODS AND SYSTEMS FOR FORMING MULTI-LAYERED PARTICLES | Final Rejection | Nulixir Inc. |
| 18198266 | Manufacturing Process for Metaxalone Tablets | Non-Final OA | Primus Pharmaceuticals, inc. |
| 17773356 | ORGANIC SELENIUM ENRICHED EDIBLE MARINE MICROALGAL BIOMASS | Non-Final OA | Council of Scientific and Industrial Research (An Indian Registered Body Incorporated Under The |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy